GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH · the Global Health Economics and Outcomes Research department at Allergan, where she was involved in systematic literature review and

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCHFELLOWSHIP PROGRAMUNIV OF WASHINGTON2019-2021

AGN7980_Allergan UW Fellowship Brochure_2018-mech.indd 1 10/15/18 10:26 AM

GHEOR Fellowship Program 2019-2021GHEOR Fellowship Program 2019-2021GHEOR Fellowship Program 2019-2021GHEOR Fellowship Program 2019-2021GHEOR Fellowship Program 2019-2021GHEOR Fellowship Program 2019-2021

PRODUCT VALUE PROPOSITION…outcomes research strategy based on product value, stakeholder needs & insights

VALUE COMMUNICATION …about evidence informing the value proposition to stakeholders

…informs health care decision making

EVIDENCE GENERATION AND TOOL DEVELOPMENT…through clinical and health economics & outcomes research (HEOR) data

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in

a new industry model – Growth Pharma. We are focused on developing, manufacturing and commercializing branded

pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

We market a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical

aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

We are an industry leader in Open Science, a model of research and development, which defi nes our approach to

identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan

has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline

programs currently in development. Learn more at www.Allergan.com.

ABOUT OUR COMPANY

OUR WORLD-CLASS MANUFACTURING AND R&D NETWORK

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH (GHEOR)

1

2

3

1 GHEOR Fellowship Program 2019-2021

USABranchburg, NJ Cincinnati, OHNorthern CA (Biologics)Irvine, CA (Biologics)Dublin, CAWaco, TXHouston, TXBridgewater, NJIrvine, CAPleasanton, CASunrise, FLMadison, NJ

COSTA RICASan Jose

BRAZILGuarulhosSão Paulo

IRELANDClonshaughGalwayWestport

BELGIUMLiege

GERMANYWeiterstadt

FRANCEPringyPringy

MANUFACTURING CANADAMarkham

CHINABeijingShanghai

JAPANTokyo

UKLiverpoolMarlow

R&D

SINGAPORESingapore


The University of Washington is a world-class leader in health sciences education and has been consistently listed in

US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly

noted for its strong research programs and since 1974 has received more federal funds for research and training

than any other public university in the United States. It fosters a highly collegial atmosphere between departments

and academic units, creating a particularly attractive environment for such partnerships between the public and

private sectors.

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute is housed within the University of

Washington School of Pharmacy, which boasts nearly 125 years of academic and research success. Faculty in the

program (1) provide advanced research training for graduate students, post-doctoral fellows and clinicians (PharmDs,

MDs); (2) conduct rigorous scientific research in economic evaluations and outcomes of pharmaceuticals and other

health technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare

policy, with the goal of improving patient care.

The CHOICE Institute faculty participating in the fellowship have been chosen both for their dedication to teaching and

their excellence in research. Each is trained either as a health economist or health services researcher and all have an

extensive history of eff ective economic evaluations and pharmacoepidemiologic research.

ABOUT OUR SCHOOL

GHEOR Fellowship Program 2019-2021 2


GHEOR Fellowship Program 2019-2021

UNIVERSITY OF WASHINGTON

Beth Devine, PharmD, MBA, PhD, FASHP

Professor, Director of Graduate Programs

The Comparative Health Outcomes, Policy,

and Economics (CHOICE) Institute

1959 NE Pacifi c St, H-375D

Box 357630

Seattle, WA 98195-7630

E-Mail: [email protected]

THE FELLOWSHIP PROGRAM Allergan and the University of Washington are pleased to off er two, 2-year GHEOR Fellowship positions for the academic

year 2019-2021. Fellows will spend their fi rst year at the University of Washington (Seattle, WA), and the second year at

Allergan (Irvine, CA). The objective of the fi rst year is to educate fellows on the principles and methods used in health

economics and outcomes research. During the second year, fellows are provided with opportunities to gain practical

knowledge and experience with the use of clinical, economic, and humanistic data by supporting the development and

commercialization of pharmaceutical products. This will be accomplished by participating in work activities undertaken

by the GHEOR team.

Compensation includes a competitive stipend, basic medical insurance, conference attendance, relocation from

Seattle to Irvine, and holiday/vacation time. A Master’s (MS) Degree is awarded upon completion of all course

requirements and thesis project.

ALLERGAN PLC

Patrick Gillard, PharmD, MS

Executive Director, General Medicine,

Global Value and Evidence

2525 Dupont Drive

Irvine, CA 92612


Phone: (714) 246-2354

FELLOWSHIP DIRECTORS

The Allergan/University of Washington GHEOR Fellowship is a two-year program that provides training and hands-on experience in a broad-range of health economics and outcomes research topics. The program is structured to allow fellows to gain profi ciency in health outcomes strategy and research as conducted

in both academic and pharmaceutical industry settings.

3

ABOUT OUR FELLOWSHIP



FIRST YEAR OBJECTIVESThe objective of the fi rst year is to provide the fellow with the research tools necessary for economic evaluation and

policy assessment. The fellow will be given an overview of pharmaceutical economics and general health policy,

and taught methods of economic assessment, health services research, epidemiology, clinical research design, and

biostatistical analyses.

The fellow will be assigned a MS thesis project which is selected based on input from both Allergan as well as the

University of Washington mentors. Fellows are highly encouraged to complete their MS project during their fi rst year.

Additionally, fellows will also engage in ongoing projects with Allergan throughout their fi rst year, applying skills from

previous pharmacy training as well as integrating new techniques developed from University of Washington courses.

Applying learning to solve real-world problems is a constant focus of the fellowship.

The fellow’s actual course of study will be developed on an individual basis with the Program Director, Dr. Beth Devine,

but will consist of courses in biostatistics, epidemiology, economic evaluations and outcomes research, and health

and pharmaceutical policy.

AFTER COMPLETION OF THE FIRST-YEAR, THE FELLOW WILL HAVE A CLEAR UNDERSTANDING OF:• General principles of economics and in particular how economics infl uences the use, cost, and availability

of pharmaceuticals.

• The complex structure of drug policy and how it determines relationships between consumers, health care providers,

insurers, payers, and government agencies.

• The breadth and scope of analytical methods needed for the assessment of Patient Reported Outcomes (PROs),

economic modeling, retrospective database studies, and observational studies.

• Formulary development, maintenance and evaluation in institutional, managed care, and state-level

government programs.

1ST YEAR

FELLOWSHIP STRUCTURE

4



SECOND YEAR OBJECTIVESThe second year of training will be at Allergan in Irvine, CA with the GHEOR department. This part of the program

is designed to allow the fellow to learn about the role of economic evaluations and outcomes research in the drug

development and commercialization process within the industry setting. The research may be on an existing or

experimental product, for a disease state that is of interest to Allergan.

In addition to completing individual research project(s), fellows will participate in ongoing economic evaluations,

outcomes research, and other projects in collaboration with the GHEOR team. These experiences will provide

the fellow with opportunities to interact with team members in other

departments at Allergan to learn how economic analyses and outcomes

research are used throughout the pharmaceutical industry. Fellows will

see fi rsthand how outcomes research is utilized to demonstrate the

place of Allergan products in treatment pathways and its value.

2ND YEAR

5



Jonathan W. Kowalski, PharmD, MS

Vice President, US HOV

Sepideh Varon, PhDAssociate Vice President, GHEOR

David Macarios, MBA, MSc

Vice President, GEV

Hema Viswanathan, BPharm, PhD

Executive Director, GHEOR

Amy Tung, PharmD, MS

Senior Manager, GHEOR



Joanna Campbell, PhDExecutive Director, GHEOR

ALLERGAN FELLOWSHIP MENTORS

Vaishali Patel, PharmD, MS


UNIVERSITY OF WASHINGTON PROGRAM FACULTY• Anirban Basu, PhD Professor and Stergachis Family Endowed

Director of The CHOICE Institute

• Denise Boudreau, PhD Affi liate Professor

• Beth Devine, PharmD, MBA, PhD, FASHP

Professor, Director of Graduate Programs

• Josh Carlson, MPH, PhD Associate Professor

• Louis P. Garrison, Jr., PhD Professor Emeritus

• Ryan Hansen, PhD, PharmD Assistant Professor

• Thomas K. Hazlet, PharmD, Dr. PH Associate Professor

• Scott D. Ramsey, MD, PhD Professor

• Sean D. Sullivan, PhD Professor and Dean of

School of Pharmacy

• David L. Veenstra, PharmD, PhD Professor and Associate Director of

The CHOICE Institute

• Joseph Babigumira, MBChB, MS, PhD

Adjunct Associate Professor

• Aasthaa Bansal, PhD Assistant Professor

• Andy Stergachis, BPharm, PhD Professor and Associate Dean for Research,

Graduate Programs and New Initiatives

• Douglas Barthold, PhD Research Assistant Professor

• Shelly Gray, PharmD, MS Professor

• Zachary Marcum, PharmD, MS, PhD

Assistant Professor

6

Anand Shewale, MS, PhD


Sarah Baradaran, PharmD, MS


Kate Burslem, MScExecutive Director, GHEOR

Mousam Parekh, MSManager, GHEOR



JAMIE TA, PHARMDJamie received her PharmD from the University of California, San Diego Skaggs School of Pharmacy and

Pharmaceutical Sciences in 2018. Prior to the fellowship, Jamie gained experiences in HEOR, managed care,

corporate development, and market access in the pharmaceutical industry, PBM, health plan, and consulting

settings. Throughout pharmacy school, Jamie worked at MedImpact Healthcare Systems, Inc., where

she worked on outcomes research, specialty pharmacy, and analytics projects to support clinical product

development. Jamie also served as the AMCP/Pfi zer, Inc. Managed Care Pharmacy Intern at SelectHealth,

where she conducted a retrospective claims database analysis to evaluate real-world adherence and clinical

outcomes of new diabetes medications in a managed care plan population. Jamie completed a rotation in

the Global Health Economics and Outcomes Research department at Allergan, where she was involved

in systematic literature review and claims database studies to support a Phase 3 product. At UCSD, Jamie

served as President of the AMCP-UCSD student chapter and was a member of UCSD’s winning national P&T

Competition team.

Jamie is excited to work with the UW CHOICE faculty and Allergan team to further develop her skills in HEOR.

For her thesis, she will be using MarketScan data to determine adherence, healthcare resource utilization, and

costs among patients treated with antidepressants.

ASHLEY KIM, PHARMDAshley is a graduate from the University of California, San Francisco (UCSF) School of Pharmacy. Prior to joining

the fellowship, she was a Health Economics & Outcomes Research intern at Genentech, where she analyzed

the epidemiology of multiple cancer types using the SEER database for budget impact analyses, assessed

patient-reported outcome data, and informed research strategy around assessing the cost of adverse events in

oncology. During her time at UCSF, she further conducted a systematic literature review surrounding the virtual

healthcare landscape and completed a clerkship in Pricing, Reimbursement, and Market Access at Eli Lilly,

where she analyzed the impact of value-based frameworks on an existing oncology drug to evaluate internal

value and access assumptions and forecasting.

Ashley is very excited to join the CHOICE institute and learn from exceptional faculty and hone her skills in

economic modeling, real world evidence generation, and outcome analyses. For her thesis, she will be using

Truven MarketScan data to characterize the disease burden and progression of geographic atrophy.

1ST YEAR FELLOWS

CURRENT FELLOWS

7



SARA HIGA, PHARMD, MSSara received her PharmD from the University of Maryland Baltimore and her BS and MS degrees from

Georgetown University. For the fi rst year of the fellowship, Sara worked under the mentorship of Drs. Aasthaa

Bansal, Beth Devine, Vaishali Patel, and Sarah Baradaran. At the University of Washington, she conducted a

retrospective claims analysis to describe psoriasis treatment patterns for her master’s thesis.

Currently, she is working with Vaishali Patel, Mousam Parekh, and Julie Garcia to support breast reconstruction

and Botox projects. Sara is excited to continue her training and apply her skills in real-world evidence, patient-

reported outcomes research, and economic evaluation.

ABSTRACTS FROM FELLOWSHIP: 1. Higa S, Rueda JD, Devine B. Cost-Utility Analysis of Initial Treatment with Apremilast versus Methotrexate

in Systemic-Naïve Patients with Plaque Psoriasis. ISPOR 23rd Annual International Meeting, May 2018,

Baltimore, MD. (Poster)

2. N’Dri L, Higa S. A Cost-Utility Analysis of Atovaquone-Proguanil vs. Artemether-Lumefantrine for the

Treatment of Uncomplicated Malaria in the U.S. ISPOR 23rd Annual International Meeting, May 2018,

Baltimore, MD. (Poster)

3. Higa S, Devine B. Psoriasis Treatment Patterns: A Systematic Review. UW Corporate Advisory Board Meeting,

September 2017, Seattle, WA. (Poster)

MANUSCRIPTS FROM FELLOWSHIP:

1. Higa S, Devine B, Patel V, Baradaran S, Wang D, Bansal A. Psoriasis Treatment Patterns: A Retrospective

Claims Study. (In Progress)

CHIEMEKA IKE, MPH, PHARMD, MSChiemeka received her PharmD from the University of Houston and her MPH in Epidemiology and Biostatistics

from the George Washington University. For the fi rst year of the fellowship, Chiemeka worked under the

mentorship of Drs. Beth Devine, Zachary Marcum, Hema Viswanathan, and Anand Shewale. For her master’s

thesis, she analyzed a cross-sectional survey using Adelphi Real-World® data to describe treatment patterns

for acute medications of migraine.

Currently, she is working with Anand Shewale and Hema Viswanathan to support various migraine projects.

Chiemeka is excited to continue her training and continue to hone her skills in real-world evidence, patient-

reported outcomes research, and health economic evaluation.

ABSTRACTS FROM FELLOWSHIP:1. Ike C, Devine B. Cost-Utility Analysis of Oral Sumatriptan Versus Oral Ergotamine/Caff eine in the Treatment

of Acute Migraine Attacks. ISPOR 23rd Annual International Meeting, May 2018, Baltimore, MD. (Poster)

2. Ike C, Devine B. Treatment, Switching, and Cycling Patterns of Acute Medications for Migraine: A Systematic

Review. UW Corporate Advisory Board Meeting, September 2017, Seattle, WA. (Poster)

MANUSCRIPTS FROM FELLOWSHIP:1. Ike C, Marcum Z, Shewale A, Viswanathan H, Cotton S, Johnson C, Jackson J, Devine B. Treatment Patterns,

Discontinuation and Switching of Acute Medications for Migraine: A Cross-Sectional Survey of Real-World

Evidence from a Multi-Country Perspective. (In Progress)

2ND YEAR FELLOWS

8



Senior Manager, Global Health Economics and Outcomes Research

Allergan plc, Irvine, CA

MANUSCRIPTS FROM FELLOWSHIP1. Shih V, Campbell J, Devine EB. The Association between Onset of Vision Impairment and Functional Limitations and Informal Caregiving

Requirements in Older Americans. (In Progress)

Pharmacy Quality, Utilization, and Clinical Programs Coordinator Kaiser Permanente of Washington

Seattle, WA

MANUSCRIPTS FROM FELLOWSHIP 1. Yep T, Patel VD, Slejko JF, Devine EB. Comparing Total and Disease Related Healthcare Cost for Glaucoma Patients by Disease Severity: A

Retrospective Claims Database Analysis. (In Progress)



MANUSCRIPTS FROM FELLOWSHIP 1. Keyloun KR, Hansen R, Hepp Z, Gillard P, Thase M, Devine EB. Adherence and Persistence Across Antidepressant Therapeutic Class: A

Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs. 2017 May;31(5):421-432.2. Mathias P, Hendrix N, Wang W, Keyloun KR, Khelifi M, Tarcyzy-Hornoch P, Devine EB. Characterizing pharmacogenomic-guided

medication use with a clinical data repository. Clin Pharmacol Ther. 2017 Aug;102(2):340-348.3. Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for

Pharmacogenomic Biomarker-Guided Medication Use. AMIA Joint Summits on Translational Science. 2017 Jul; eCollection.

PAST FELLOWS

KATELYN KEYLOUN

PharmD, MS2014-2016

VANESSA SHIH

PharmD, MS2014-2016

TRACY YEPPharmD, MS

2013-2015

Associate Health Economist, Evidence for Access (BioOncology) - US Medical AffairsGenentech, Inc., San Francisco, CA

MANUSCRIPTS FROM FELLOWSHIP1. Shapouri S, Devine EB, Keyloun KR, Gillard PJ, Sabbatini AK, Bansal A. Predicting Hospitalizations and Returns to the Emergency

Department 30-Days Post Emergency Department Discharge Among Patients with Acute Bacterial Skin and Skin Structure Infections. (In Progress)

SHEILA SHAPOURIPharmD, MS

2016-2018

Manager, Medical Affairs (HEOR)Neurocrine Biosciences, San Diego, CA

MANUSCRIPTS FROM FELLOWSHIP1. Serbin M, Devine B, Campbell J, Basu A. Assessing the Societal Burden of Glaucoma Patients With vs. Without Physical or Mental

Comorbidities. (In Progress)

MICHAEL SERBIN

PharmD, MS2016-2018

9



MANUSCRIPTS FROM FELLOWSHIP 1. Tung A, Hepp Z, Bansal A, Devine EB. Characterizing Health Care Utilization, Direct Costs, and Comorbidities Associated with Interstitial

Cystitis: A Retrospective Claims Analysis. Journal of managed care & specialty pharmacy. 2017; 23(4):474-482. 2. Dmochowski R, Brucker B, Cole E, Kawahara S, Pulicharam R, Burk C, Tung A, Hale D. Economic Burden of Illness in Adult Patients with

Nocturia. (In Progress)

AMY TUNG

PharmD, MS2015-2017



MANUSCRIPTS FROM FELLOWSHIP 1. Baradaran S, Black D, Keyloun K, Hansen R, Gillard P, Devine B; The Impact of Acute Kidney Injury on the Risk of Mortality and Health Care

Utilization Among Patients Treated With Polymyxins for Severe Gram-Negative Infections, Open Forum Infectious Diseases, Volume 5, Issue 8, 1 August 2018.

2. Kagan R, Martin A, Sarri G, Guo Y, Baradaran S, Harrington A. The Burden of Illness Associated with Symptomatic Vulvovaginal Atrophy (VVA): A Systematic Review. (In Progress)

3 Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2017; 2017:30-39.

SARAH BARADARAN

PharmD, MS2015-2017



Health Economist

Genentech, San Francisco, CA

MANUSCRIPTS FROM FELLOWSHIP1. Stewart Williams JA, Wallick CJ, Byles JE, Doran CM.Assessing patterns of use of cardio-protective polypill component medicines in

Australian women. Drugs Aging (2013)30:193-2032. Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD. Comorbidity and Health Care Resource Use Among Commercially

Insured Non-Elderly Patients With Diabetic Macular Edema. Ophthalmic surgery, lasers & imaging retina. 2015 Jul-Aug;46(7):744-513. Wallick CJ, Sullivan SD, Hansen RN, Campbell JH, Kowalski JW. The Cost of Diabetic Macular Edema in a Commercially Insured Working

Age Population Opthalmic Surg Lasers Imaging Retina. 2015 Jul-Aug;46(7):744-51

CHRIS WALLICK

PharmD, MS2012-2014

Associate Director, Patient Reported Outcomes The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ

MANUSCRIPTS FROM FELLOWSHIP1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder with Urinary

Urge Incontinence Refractory to Oral Antimuscarinics: A Review of Published Evidence. BMC Urology, 2009; 9(18)

Associate Professor, UCSD Skaggs School of PharmacySan Diego, CA

MANUSCRIPTS FROM FELLOWSHIP1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder with Urinary Urge

Incontinence Refractory Oral Antimuscarinics. BMC Urology, 2009 Nov;20;9(18).2. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost Analysis of Interventions for Antimuscarinic Refractory

Patients with Overactive Bladder. Urology, 2010 Oct;76(4):835-40.3. Sand P, Rovner E, Dmochoswki R, Watanabe JH, Oefelein MG. Once-daily Trospium Chloride 60 mg Extended Release is Safe and Effective in

Subjects with the Overactive Bladder Syndrome who Use Multiple Concomitant Medications. Drugs Aging, 2011 Feb;1;28(2):151-604. Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. Curr Med Res

Opin, 2011 May, 27(5):1041-8.

Executive Director, Global Health Economics and Outcomes Research


MANUSCRIPTS FROM FELLOWSHIP1. Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD. Mapping from Disease- Specific Measures to Health-State Utility Values in Individuals

with Migraine. Value in Health 2012;15(3):485-94.2. Doan QV, Brashear A, Gillard PJ, Varon SF, Turkel CC, Vandenburgh AM, Elovic EP. Relationship Between Disability Due to Upper-Limb

Post-Stroke Spasticity and Health-Related Quality of Life and Caregiver Burden, PM&R 2012;4(1):4-10.

Associate Director, Health Economics and Outcomes Research

Kite Pharma, Santa Monica, CA

MANUSCRIPTS FROM FELLOWSHIP1. Lin VW, Ringold S, Devine BE. Comparison of Ustekinumab with other Biologic Agents for Treatment of Moderate-to-Severe Psoriasis:

A Bayesian Network Meta-Analysis. Arch Dermatol. 2012 Dec;148(12):1403-102. Lin VW, Wright A, Flum DR, Alfonso RA, Garrison LP, Sullivan SD. Patients’ experience and outcomes after laparoscopic adjustable gastric

banding in Washington State. Surg Obes Relat Dis. 2013 Sep-Oct;9(5):701-53. Lin VW, Wong ES, Wright A. Association between health-related quality of life and body mass after adjustable gastric banding: a

nonlinear approach. Value in Health. 2013 Jul;16(5):823-9

Consultant, Health Economics and Outcomes Research

Seattle, WA

MANUSCRIPTS FROM FELLOWSHIP1. JC Sanderson, EB Devine, RB Lipton, LM Bloudek, SF Varon, AM Blumenfeld, PJ Goadsby, DC Buse, SD Sullivan. Headache-related health

resource utilization in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1309-172. Messali A, Sanderson JC, Blumenfeld AM. Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based

Survey. Headache. 2016 Feb;56(2):306-22

JONATHAN H. WATANABE

PharmD, MS, PhD2007-2009

Associate Director, Health Economics and Outcomes Research

Seattle Genetics, Seattle, WA

MANUSCRIPTS FROM FELLOWSHIP1. Hepp Z, David DW, Gillard P, Varon SF, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with

chronic migraine. Cephalalgia. 2015 May;35(6):478-88.2. Forrester S, Hepp Z, Roth J, Wirtz H, Devine EB. Cost-effectiveness of a computerized provider order entry system in improving

medication safety in ambulatory care. Value Health. 2014 Jun;17(4):340-9

ZSOLT HEPPPharmD, MS

2012-2014

JOANNA SANDERSON

PharmD, MS2011-2013

VINCENT W. LIN

PharmD, MS2010-2012

PATRICK GILLARD

PharmD, MS2009-2010

KATHARINE S. GRIES

PharmD, MS, PHD2008-2010

10


NYSE:AGN | www.Allergan.com

© 2018 Allergan. ® Marks owned by Allergan. All rights reserved

APPLICATION INFORMATIONInterested students must apply to both the University of Washington Graduate

School, as well as the The Comparative Health Outcomes, Policy, and Economics

(CHOICE) Institute. The online application process can be found at:

https://sop.washington.edu/choice/graduate-education-training-programs/

fellowships/

CONTACT INFORMATIONIf you have any questions, please contact:

UNIVERSITY OF WASHINGTON

Shannon Dwyer

Program Operations Specialist

1959 NE Pacific St

Box 357630

Seattle, WA 98195-7630


Phone: (206) 616-1383

Fax: (206) 543-3835

DEADLINE The application deadline is

December 7, 2018

and the start date of the

Fellowship is July 1, 2019

ALLERGAN PLC



2525 Dupont Drive

Irvine, CA 92612


Phone: (714) 246-2354

Applicants for this fellowship must have a degree in pharmacy and have some

research experience (preference will be given to those with a high academic

standing). Excellent written and verbal communication skills are also essential.

Applicants will be required to submit their curriculum vitae, a letter

describing their career goals, and three letters of recommendation.

Selection of fellows will be made by a steering committee

composed of the University of Washington faculty

members and representatives from Allergan.

APPLICATION ELIGIBILITY

UniversityUNIVERSITY OF WASHINGTONThe Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute

Programs Offered

University Location

Allergan Location

Program Length

Eligibility

Seattle, WA

Irvine, CA

2 years

Degree in Pharmacy

Global Health Economics and Outcomes Research

A L L E R G A N F E L LO W S H I P P R O G R A M S


Documents

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH · the Global Health Economics and Outcomes Research department at Allergan, where she was involved in systematic literature review and